JP2018522571A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522571A5
JP2018522571A5 JP2018506513A JP2018506513A JP2018522571A5 JP 2018522571 A5 JP2018522571 A5 JP 2018522571A5 JP 2018506513 A JP2018506513 A JP 2018506513A JP 2018506513 A JP2018506513 A JP 2018506513A JP 2018522571 A5 JP2018522571 A5 JP 2018522571A5
Authority
JP
Japan
Prior art keywords
seq
cells
cancer
domain
hexameric protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018506513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522571A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/069175 external-priority patent/WO2017025610A1/en
Publication of JP2018522571A publication Critical patent/JP2018522571A/ja
Publication of JP2018522571A5 publication Critical patent/JP2018522571A5/ja
Pending legal-status Critical Current

Links

JP2018506513A 2015-08-12 2016-08-11 Gitrl融合タンパク質およびその使用 Pending JP2018522571A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562204212P 2015-08-12 2015-08-12
US62/204,212 2015-08-12
US201662350447P 2016-06-15 2016-06-15
US62/350,447 2016-06-15
PCT/EP2016/069175 WO2017025610A1 (en) 2015-08-12 2016-08-11 Gitrl fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2018522571A JP2018522571A (ja) 2018-08-16
JP2018522571A5 true JP2018522571A5 (cg-RX-API-DMAC7.html) 2019-09-12

Family

ID=56740217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506513A Pending JP2018522571A (ja) 2015-08-12 2016-08-11 Gitrl融合タンパク質およびその使用

Country Status (17)

Country Link
US (2) US10428131B2 (cg-RX-API-DMAC7.html)
EP (1) EP3334758A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018522571A (cg-RX-API-DMAC7.html)
KR (1) KR20180033588A (cg-RX-API-DMAC7.html)
CN (1) CN108026158A (cg-RX-API-DMAC7.html)
AU (1) AU2016306625A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018002039A2 (cg-RX-API-DMAC7.html)
CA (1) CA2994346A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018000358A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018002450A2 (cg-RX-API-DMAC7.html)
HK (2) HK1250044A1 (cg-RX-API-DMAC7.html)
IL (1) IL257113A (cg-RX-API-DMAC7.html)
MX (1) MX2018001787A (cg-RX-API-DMAC7.html)
RU (1) RU2018108236A (cg-RX-API-DMAC7.html)
TW (1) TW201718632A (cg-RX-API-DMAC7.html)
WO (1) WO2017025610A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201801640B (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016007965A (es) * 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
MY206406A (en) 2015-10-02 2024-12-16 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
WO2018215506A1 (en) * 2017-05-23 2018-11-29 Université De Genève Beta-2-glycoprotein 1 derived peptide and use thereof for treating antiphospholipid syndrome
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
WO2018234879A1 (en) 2017-06-22 2018-12-27 Novartis Ag USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
CN111050791A (zh) 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
BR122022012697B1 (pt) 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2021531306A (ja) 2018-07-25 2021-11-18 アドバンスド アクセラレーター アプリケーションズ エスエー 神経内分泌腫瘍の処置の方法
AU2019321490B2 (en) * 2018-08-13 2025-09-04 Inhibrx Biosciences, Inc. Ox40-binding polypeptides and uses thereof
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2022516850A (ja) 2018-12-21 2022-03-03 ノバルティス アーゲー 骨髄異形成症候群の治療又は予防におけるIL-1β抗体の使用
US20220056123A1 (en) 2018-12-21 2022-02-24 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CN115867662A (zh) * 2020-04-22 2023-03-28 浦项工科大学校产学协力团 形成三聚体的新型冠状病毒肺炎(covid-19)重组刺突蛋白、在植物中大量产生重组刺突蛋白的方法和基于其制备疫苗组合物的方法
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
US20230235007A1 (en) * 2020-06-15 2023-07-27 Ming-Che Shih Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN113429488B (zh) * 2021-07-14 2022-08-30 海正生物制药有限公司 GITR/TGF-β双靶向融合蛋白及其用途
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2026087747A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
WO2026087748A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
CN1809589A (zh) * 2003-05-23 2006-07-26 Wyeth公司 Gitr配体和gitr配体相关分子和抗体及其应用
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
EP1877090B1 (en) * 2005-05-06 2014-01-15 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
TWI476001B (zh) * 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Fc融合蛋白及其用途
WO2015116178A1 (en) * 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
CN106456734A (zh) 2014-05-29 2017-02-22 免疫医疗有限责任公司 Ox40l融合蛋白及其用途

Similar Documents

Publication Publication Date Title
RU2018108236A (ru) Слитые белки на основе gitrl и пути их применения
US12173082B2 (en) Bispecific polypeptides against CD137
US11780928B2 (en) Polypeptides
US20220169751A1 (en) Multimeric ox40 binding molecules and uses thereof
AU2017299610B2 (en) Multimeric CD40 binding molecules and uses thereof
TWI819024B (zh) 結合至ilt4的抗體
AU2015321546B2 (en) Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
JP2021118754A (ja) Cd38に結合する抗体治療剤
CA3142738A1 (en) Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
CN110709421A (zh) 针对ox40和ctla-4的双特异性抗体
JP7128819B2 (ja) Adam9結合分子、およびその使用方法
RU2016150096A (ru) Белки слияния на основе ox40l и пути их применения
CN116333138A (zh) Pd-1结合分子和其使用方法
WO2018217988A9 (en) MODIFIED IGG1 FC DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS WITH THE SAME
US20220073635A1 (en) Novel polypeptides
US11873348B2 (en) Peptides
WO2022125712A9 (en) Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
CA3220027A1 (en) Bispecific fc fusion proteins with spd-1 and il-15
HK40073076A (en) Anti-cd137 antibodies
HK40004686B (en) Novel bispecific polypeptides against cd137
HK1241895A1 (en) Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
HK1241895B (en) Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof